Medtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensor
MWN-AI** Summary
Medtronic, a leader in healthcare technology, has launched the MiniMed Go™ Smart MDI system with the Simplera™ sensor in Europe. This innovative system is the first of its kind to integrate data from the InPen™ smart insulin pen and the Simplera™ sensor into a single mobile application. Targeted at individuals who manage their diabetes with multiple daily injections (MDI), the system aims to enhance glycemic control through real-time insights and multi-faceted support.
The MiniMed Go™ system distinguishes itself from traditional connected insulin pens by offering personalized alerts, a dose calculator, and continuous guidance—all within an accessible smartphone application. Recognizing the significant impact of missed doses on diabetes management, the system encourages adherence by alerting users to missed doses, which can exacerbate glycemic levels and ultimately lead to complications.
Clinical studies have illustrated that timely response to missed dose alerts can significantly improve Time in Range (TIR)—a vital metric for effective diabetes management. The new CareLink Clinic feature also promises to streamline data interpretation for healthcare providers, enabling more informed discussions with patients.
This launch in Europe is particularly expansive, as the MiniMed Go™ system will be available for insulin-dependent individuals aged 7 and older, with additional provisions for younger children under an adult’s supervision. Medtronic underscores the shift towards smarter, data-driven diabetes management, merging telemedicine with advanced technology for more personalized care solutions.
With the MiniMed Go™ Smart MDI system, Medtronic aims to revolutionize how diabetes is managed on a daily basis, enhancing both patient experience and health outcomes through technology-driven insights.
MWN-AI** Analysis
Medtronic's recent launch of the MiniMed Go Smart MDI system with the Simplera sensor represents a significant advancement in diabetes management technology, particularly for patients utilizing multiple daily injections (MDI). As this system gradually rolls out across Europe, potential investors should consider both the market implications and competitive positioning of Medtronic (NYSE: MDT) in this evolving sector.
The MiniMed Go system distinguishes itself by integrating real-time glucose monitoring data with the InPen smart insulin pen through a user-friendly mobile app. This innovation not only enhances patient engagement but also addresses critical issues like missed insulin doses — a common barrier to effective diabetes management. With research indicating that missed doses can significantly elevate HbA1C levels and negatively impact Time in Range (TIR), the system’s alerts and guidance features position it favorably against traditional MDI solutions.
Investors should assess how this new offering can enhance Medtronic's competitive edge in the medical technology market, particularly within the diabetes care segment. The company has consistently innovated in this space, and as evidence mounts regarding the efficacy of data-driven decision support for diabetes patients, it may attract both greater adoption and insurance reimbursement support.
Moreover, the pending integration of the Instinct Go sensor expands Medtronic's allure, appealing to diverse patient preferences regarding sensor use. As telemedicine gains momentum, the added ability to provide remote patient support through CareLink Clinic MDI reports could further solidify Medtronic's position as a leader in personalized healthcare, fostering stronger provider-patient relationships.
Overall, Medtronic's strategic focus on technological integration could positively influence its market performance. Investors should keep an eye on sales metrics post-launch and consider the broader impact of regulatory approvals on product adoption. Maintaining awareness of competitor responses and market trends in diabetes care technology will be essential for making informed investment decisions in this dynamic landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Real-time actionable insights on one mobile app for people who manage their diabetes using multiple daily injections
GALWAY, Ireland, Feb. 25, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the commercial launch in Europe of the MiniMed Go™ Smart MDI system with the Simplera™ sensor. The system, which is the first and only solution to integrate data from the InPen™ smart insulin pen and the Simplera™ sensor into a single mobile app, is designed to help people who use multiple daily injections (MDI) to better control their diabetes. The launch will be rolled out gradually across Europe starting this month.
The MiniMed Go™ Smart MDI system marks a departure from traditional and basic connected insulin pens. It provides real-time, personalized insights, actionable dose alerts, a built-in advanced dose calculator, and continuous guidance — all accessible through a smartphone app. This intelligent decision support tool aims to address daily challenges faced by those managing diabetes with MDI.
Missing insulin doses (boluses) can significantly impact glycemic control. Research shows that skipping just two doses per week may increase HbA1C by up to 0.4,1 raising the risk of both short- and long-term complications.2 Another study found that missing two basal doses or four bolus doses over 14 days was linked to more than a 5% decrease in Time in Range.3 Real-world data 4 from the previous generation of the Medtronic Smart MDI system demonstrated that users who responded to more than 75% of missed dose alerts within one hour achieved Time in Range (TIR) of 67.2% compared to the mean TIR for the cohort at 55.7%, and up to 71.5% TIR when addressing high blood sugar alerts.
"Real-time actionable alerts are becoming the key to better clinical outcomes for people with diabetes using multiple daily injections," said Que Dallara, EVP and president of Medtronic Diabetes and CEO-designate of MiniMed. "The MiniMed Go™ system remembers, reminds and recommends the right dose at the right time so you don´t have to." †
For busy healthcare professionals, the MiniMed Go™ system includes new CareLink Clinic MDI reports, that make it easier for clinicians to interpret user data and support more informed patient discussions.
"Smart MDI has fundamentally changed how we care for patients on multiple daily injections," said Dr Martín Cuesta Hernández, Endocrinologist, Hospital Clinico San Carlos - Madrid, Spain. "We're now making evidence-based decisions instead of relying on assumptions, which has strengthened trust and improved the quality of our conversations with patients. Many people simply tell us they're delighted because life is easier. Combined with efficient telemedicine delivery, we're able to provide more personalised, effective care than ever before."
In Europe, the MiniMed Go™ system with Simplera™ sensor is approved for people with insulin-requiring diabetes aged 7 years and older, as well as for children aged 2 to 6 years under the supervision of an adult caregiver. Compatibility of the Instinct Go™ sensor, made by Abbott, with MiniMed Go™ in Europe is currently pending CE mark approval. Once approved, users will have the choice between a 7-day or 15-day sensor depending on what best fits their needs.
Frequently Asked Questions
Q: What is the MiniMed Go™ system?
A: In Europe, the MiniMed Go™ system is a smart diabetes management solution that connects the InPen™ smart insulin pen with the Simplera™ sensor through the single MiniMed Go™ app. It provides real-time glucose data, dose calculations, missed dose alerts, and actionable guidance, making MDI therapy easier and more connected. CE mark approval is pending on integration with the Instinct Go™ sensor made by Abbott. In the U.S., the MiniMed Go™ Smart Multiple Daily Injection (MDI) system seamlessly integrates the InPen™ smart insulin pen with the Instinct sensor. Compatibility of the Simplera™ sensor with MiniMed Go™ is currently under FDA review.
Q: What is InPen™?
A: The InPen™ is a reusable smart insulin pen that uses Bluetooth® technology to send dose information to a mobile app. Offering dose calculations and tracking, InPen™ helps take some of the mental math out of diabetes management.
Q: What's the difference between the MiniMed Go™ Smart MDI system and the previous Medtronic Smart MDI system with Simplera™ sensor?
A: There are a few upgrades including a single unified mobile app experience, easier onboarding, support and self-training tools, new features and insulin settings. For healthcare professionals, new CareLink Clinic dedicated MDI reports turn patient data into clinical and behavioural insights, making consultations more efficient.
Q: What is the difference between the MiniMed Go™ Smart MDI system and traditional pens or other connected pens for diabetes?
A: Unlike traditional insulin pens, which lack the ability to track doses or provide decision support, the MiniMed Go™ Smart MDI system offers integration of real-time continuous glucose monitoring, a built-in dose calculator that simplifies dose decision-making, and smart dosing alerts to help people with their diabetes therapy adherence – the first and only Smart MDI system to offer an all in one mobile app.
† Proper settings, connectivity, and some manual logging required. See user guides for full details and important safety information. |
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license. |
About the Diabetes Business at Medtronic
Medtronic Diabetes is on a mission to make diabetes more predictable with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Contacts:
Janet Cho
Public Relations
+1-818-403-7028
Ingrid Goldberg
Investor Relations
+1-763-505-2696
1 | Randlov, J, Poulsen, JU. How Much Do Forgotten Insulin Injections Matter to Hemoglobin A1c in People with Diabetes, J Diabetes Sci Technol. 2008; 2(2):229-235. |
2 | American Diabetes Association Professional Practice Committee for Diabetes. Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan |
3 | Danne TPA, Joubert M, Hartvig NV, Kaas A, Knudsen NN, Mader JK. Association Between Treatment Adherence and Continuous Glucose Monitoring Outcomes in People With Diabetes Using Smart Insulin Pens in a Real-World Setting. Diabetes Care. 2024 Jun 1;47(6):995-1003. doi: 10.2337/dc23-2176. PMID: 38569055; PMCID: PMC11116913. |
4 | Laurenzi A, Edd SN, Adolfsson P, et al. Insights into the effective use of the Smart MDI system: Data from the first 1852 type 1 diabetes users. Diabet Med. 2025;42(12):e70161. doi:10.1111/dme.70161. |
SOURCE Medtronic plc
FAQ**
How does the MiniMed Go™ Smart MDI system improve glycemic control for patients using MDI, and what evidence does Medtronic plc. MDT provide to support its effectiveness compared to traditional insulin delivery methods?
What features of the MiniMed Go™ system differentiate it from previous Medtronic offerings, and how does it integrate real-time data management to enhance patient adherence to insulin therapy?
Given the gradual rollout across Europe, what strategies is Medtronic plc. MDT employing to ensure successful adoption of the MiniMed Go™ Smart MDI system among healthcare professionals and patients?
How does the compatibility of the Simplera™ sensor with the MiniMed Go™ system impact its functionality, and what is the current status of the CE mark approval for the Instinct Go™ sensor by Medtronic plc. MDT?
**MWN-AI FAQ is based on asking OpenAI questions about Medtronic plc. (NYSE: MDT).
NASDAQ: MDT
MDT Trading
-1.36% G/L:
$89.11 Last:
3,300,055 Volume:
$90 Open:
